Capabilities by Industry

Greenhill and its Managing Directors have extensive experience in a wide range of industries, including substantially all major industry areas with meaningful corporate transaction activity.

Recent Transactions

17-Jun-13
$200 million
United States flag
Target: 

Tesoro Hawaii, LLC

United States flag
Acquiror: 
Par Petroleum

Advised the Special Committee of the Board of Directors of Par Petroleum in connection with its acquisition of Tesoro Hawaii, LLC from Tesoro Corporation

12-Jun-13
$893 million
Australia flag
Target: 

A$1.6bn non-core loan portfolio

United States flag
Acquiror: 
Goldman Sachs Group. Inc.

Advised Suncorp Group Ltd (ASX:SUN), a leading general insurance, retail banking and life insurance group in Australia and New Zealand, on the sale of a A$1.6bn portfolio of performing and non-performing (corporate and property) loans to Goldman Sachs Group Inc., an American multinational investment banking firm

31-May-13
$57 million
Australia flag
Target: 

d-cyphaTrade Limited

Australia flag
Acquiror: 
Australian Securities Exchange (ASX)

Advised Transpower New Zealand, the state owned owner-operator of New Zealand’s electricity distribution network on the sale of its wholly owned subsidiary d-cyphaTrade Limited to the Australian Securities Exchange. d-cyphaTrade specializes in the design and marketing of Australian electricity derivatives traded on the ASX24 derivatives platform

31-May-13
$500 million
Australia flag
Target: 

iSelect (30% shareholding)

Australia flag
Acquiror: 
Ninemsn (T/A Mi9)

Advised Mi9, a joint venture between Microsoft and Nine Entertainment Co, and one of Australia’s leading digital media companies, on the sale of its 30% holding in iSelect, a leading Australian online-driven comparison service, as part of the Initial Public Offering of iSelect

20-May-13
$8.5 billion
Ireland flag
Target: 

Warner Chilcott, plc

United States flag
Acquiror: 
Actavis, Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

Pages

show all